Skip to main content

Table 2 Comparison of the frequency: demographical and clinical data in aRibP-positive and negative SLE patientsa

From: Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus

  

aRibP N H

aRibP R 0

aRibP R 1

aRibP R 2

Clinical data

All patients

(n= 163)

Positive

(n= 30)

Negative

(n= 133)

P value

Positive

(n= 34)

Negative

(n= 129)

P value

Positive

(n= 24)

Negative

(n= 139)

P value

Positive

(n= 28)

Negative

(n= 135)

P value

Demographics

             

   Age in years,b median

37.0

36.5

37.0

0.317

35.0

37.0

0.081

35.0

37.0

0.326

37.0

37.0

0.467

   Age at onset,c <18 years, %

19.7

15.6

13.9

1.000

24.3

16.8

0.338

22.2

17.7

0.592

26.7

16.7

0.203

   Females,c %

89.8

84.4

91.2

0.324

89.2

90

1.000

96.3

88.7

0.314

90

89.9

1.000

   SLE duration in months,b median

108.0

97.0

109.0

0.716

69.0

109.0

0.118

62.0

109.0

0.147

96.0

107.0

0.756

ACR criteria

n = 163

n = 30

n = 133

 

n = 34

n = 129

 

n = 24

n = 139

 

n = 28

n = 135

 

   Number of ACR criteria,b median

6.00

7.00 d

6.00 d

0.031 d

7.00

6.00

0.059

6.50

6.00

0.236

7.00

6.00

0.076

   Malar rash,c %

66.2

73.3

64.6

0.402

70.6

65.1

0.684

70.8

65.5

0.815

71.4

65.2

0.662

   Discoid rash,c %

12.3

16.7

11.3

0.536

14.7

11.6

0.571

16.7

11.5

0.501

25.0

9.63

0.0504

   Photosensitivity,c %

46.6

63.3 d

42.9 d

0.046 d

58.8

43.4

0.125

62.5

43.9

0.121

53.6

45.2

0.533

   Oral ulcers,c %

18.4

23.3

17.3

0.441

23.5

17.1

0.456

12.5

19.4

0.573

17.9

18.5

1.000

   Arthritis,c %

84.1

90.0

82.7

0.417

94.1

81.4

0.111

91.7

82.7

0.373

96.4

81.5

0,0506

   Serositis,c %

44.2

36.7

45.9

0.419

38.2

45.7

0.561

41.7

44.6

0.828

39.3

45.2

0.677

   Renal disorder,c %

42.9

46.7

42.2

0.686

44.1

42.6

1.000

37.5

43.9

0.658

39.3

43.7

0.834

   Epilepsy or psychosis,c %

12.9

20.0

11.3

0.228

14.7

12.4

0.774

25.0

10.8

0.091

21.4

11.1

0.209

   Hematologic,c %

63.8

70.0

62.4

0.530

67.6

62.8

0.690

58.3

64.7

0.646

67.9

62.9

0.672

   Immune disorder and ANA, %

100

100

100

-

100

100

-

100

100

-

100

100

-

SLEDAI

n = 101

n = 17

n = 84

 

n = 22

n = 79

 

n = 17

n = 84

 

n = 17

n = 84

 

   SLEDAI,b median

6.00

6.00

6.00

0.517

6.00

6.00

0.886

6.00

6.00

0.915

6.00

6.00

0.256

   Vasculitis,c %

7.92

5.89

8.33

1.000

4.55

8.86

0.682

11.8

7.14

0.621

5.89

8.33

1.000

   Arthritis,c %

33.7

23.5

35.7

0.408

22.7

36.7

0.309

11.8 d

38.1 d

0.048 d

11.8 d

38.1 d

0.048 d

   Hematuria,c %

6.93

11.8

5.95

0.335

4.55

7.59

1.000

0.00

9.52

0.346

0.00

9.41

0.346

   Proteinuria,c %

9.90

17.6

8.33

0.366

9.09

10.1

1.000

5.88

10.7

1.000

5.88

10.7

1.000

   Exanthema,c %

32.7

11.8

36.9

0.0503

27.3

34.2

0.615

23.5

34.5

0.572

23.5

34.5

0.572

   Alopecia,c %

16.8

23.5

15.5

0.478

27.3

13.9

0.195

17.6

16.7

1.000

17.6

16.7

1.000

   Pericarditis,c %

6.93

5.88

7.14

1.000

9.09

6.33

0.645

11.8

5.95

0.335

5.88

7.14

1.000

   Complement deficiency,c %

57.4

64.7

55.9

0.597

68.2

51.2

0.331

58.8

57.1

1.000

64.7

55.9

0.597

   Fever,c %

3.96

0.00

4.67

1.000

4.55

3.79

1.000

0.00

4.76

1.000

0.00

4.76

1.000

Drugs

             

   Prednisolone,c %

89.9

93.1

89.2

0.738

90.9

89.7

1.000

86.9

90.4

0.706

88.9

90.3

0.734

   Azathioprine,c %

30.8

27.6

31.5

0.825

36.4

29.4

0.526

17.4

33.1

0.151

29.6

31.1

1.000

   Cyclophosphamide,c %

8.81

6.89

9.23

1.000

12.1

7.94

0.491

18.8

7.75

0.155

11.1

8.33

0.708

   Mycophenolate mofetil,c %

20.5

20.7

19.7

1.000

15.2

22.2

0.474

30.4

19.1

0.265

22.2

20.5

0.799

   Methotrexate,c %

3.04

3.23

3.01

1.000

8.33

1.56

0.071

7.69

2.17

0.179

3.45

2.96

1.000

   Hydroxychloroquine sulfate,c %

35.4

50.0

32.3

0.085

36.4

35.2

1.000

30.4

36.3

0.645

37.0

35.1

0.829

Laboratory

             

   Leukocytes,b median

6.50

7.03

6.40

0.539

7.00

6.30

0.136

6.58

6.40

0.479

6.50

6.49

0.933

   Lymphocytes,b median

0.87

0.67

0.87

0.164

0.63 d

0.92 d

0.036 d

0.91

0.86

0.957

0.70

0.93

0.076

   Monocytes,b median

0.35

0.34

0.35

0.769

0.33

0.35

0.584

0.48

0.35

0.301

0.31

0.35

0.540

   ALT,b,e median

19.4

14.4

20.0

0.501

22.0

19.2

0.824

20.7

19.0

0.661

14.7

20.0

0.547

   AST,b,e median

25.0

28.0

24.9

0.212

25.5

25.0

0.953

27.5

24.9

0.129

25.0

25.0

0.568

   GGT,b,e median

23.0

26.0

21.6

0.278

24.0

21.1

0.423

29.0 d

21.0 d

0.047 d

29.0

21.1

0.108

   Low C3,c %

47.6

65.5 d

43.2 d

0.038 d

58.1

44.8

0.227

54.2

46.3

0.511

61.5

44.6

0.134

   Low C4,c %

34.7

37.9

33.9

0.670

38.7

33.6

0.672

37.5

34.1

0.816

38.4

33.9

0.656

   CRP,b median

0.38

0.30

0.40

0.771

0.28

0.42

0.454

0.25

0.42

0.379

26.0

25.9

0.803

   ESR,b median

24.0

25.0

24.0

0.616

22.0

25.0

0.740

21.5

25.0

0.572

23.0

24.5

0.819

Autoantibodies

             

   High anti-Sm,c %

33.7

63.3 d

27.1 d

4 × 10 -3d

70.6 d

24.2 d

<10 -4d

66.7 d

28.1 d

7 × 10 -3d

60.7 d

28.1 d

0.002 d

   Increased anti- dsDNA in ELISA,c %

42.3

70.0 d

36.8 d

0.002 d

67.8 d

36.4 d

0.002 d

75.0 d

37.4 d

7 × 10 -3d

60.7 d

39.3 d

0.058 d

   Increased anti- dsDNA in RIA,c %

56.4

76.7 d

51.9 d

0.015 d

79.4 d

50.4 d

0.003 d

83.3 d

51.8 d

0.004 d

78.6 d

51.9 d

0.012 d

   Increased anti- U1-RNP in anamnesis,c %

28.9

59.1 d

21.7 d

0.001 d

50.0 d

23.3 d

0.021 d

62.5 d

23.5 d

0.003 d

54.5 d

22.7 d

0.007 d

   Increased anti- nucleosomes,c %

50.9

60.0

48.9

0.315

64.7

47.3

0.084

62.5

48.9

0.271

70.4 d

47.1 d

0.035 d

   Increased anti- Ro/SS-A,c %

40.5

50.0

38.3

0.304

41.2

40.3

1.000

37.5

41.0

0.824

39.3

40.7

1.000

   Increased anti- La/SS-B,c %

12.3

20.0

10.5

0.213

8.82

13.2

0.769

0.00 d

14.4 d

0.046 d

3.57

14.1

0.203

  1. aSLE, systemic lupus erythematosus; ACR, American College of Rheumatology; ANA, antinuclear antibody; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; anti-Sm, anti-Smith antibody; anti-dsDNA, anti-double-stranded DNA antibody; Ro/SS-A, anti- Sjögren's syndrome antigen A; La/SS-B, anti- Sjögren's syndrome antigen B; U1-RNP, U1-ribonucleoprotein; aRibP, anti-ribosomal P protein antibody; aRibPNH, antibodies against native ribosomal P heterocomplex; aRibPR0, antibodies against recombinant ribosomal P0 protein; aRibPR1, antibodies against recombinant ribosomal P1 protein; aRibPR2, antibodies against recombinant ribosomal P2 protein. All used autoantibody cutoffs were read out of receiver-operating characteristics analysis at a specificity of 98% (see Table 1); bP values were calculated using the Mann-Whitney U test; cP values were calculated using Fisher's exact test; dstatistically significant findings, highlighted in bold; eGGT values of men and from other laboratories have been standardized on cutoffs of GGT for women at the Charité University Hospital.